Entero Therapeutics (NASDAQ:ENTO) Trading 1.5% Higher – Time to Buy?

Shares of Entero Therapeutics, Inc. (NASDAQ:ENTO) traded up 1.5% during trading on Thursday . The stock traded as high as $3.49 and last traded at $3.33. 115,128 shares were traded during trading, a decline of 9% from the average session volume of 126,532 shares. The stock had previously closed at $3.28.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ENTO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Entero Therapeutics in a research report on Tuesday, October 14th. Wall Street Zen upgraded Entero Therapeutics to a “hold” rating in a research note on Friday, October 3rd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Entero Therapeutics Stock Performance

The firm has a 50 day moving average price of $3.27 and a two-hundred day moving average price of $3.12. The company has a market capitalization of $5.29 million, a P/E ratio of -1.97 and a beta of 1.19.

Institutional Trading of Entero Therapeutics

An institutional investor recently bought a new position in Entero Therapeutics stock. Virtu Financial LLC bought a new stake in shares of Entero Therapeutics, Inc. (NASDAQ:ENTO) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned 0.74% of Entero Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 12.30% of the company’s stock.

About Entero Therapeutics

Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development.